Johnson & Johnson MedTech (NYSE: JNJ) today announced the first completed commercial case with its Varipulse platform in ...

Johnson & Johnson's innovative medicines division shows promise with expected revenues of $57bn by 2025. See more about JNJ ...

Johnson & Johnson's Q3 2024 results surpassed analyst expectations, reporting $2.42 EPS and $22.47 billion in sales. Updated ...

Johnson & Johnson’s medtech acquisitions over the past year have fueled growth for its cardiovascular group, offsetting challenges in businesses like orthopedics and surgery.

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on third-quarter financial results and a surgical ...

Johnson & Johnson (NYSE:JNJ) lowered its full-year earnings outlook on Tuesday despite posting better-than-expected ...

Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.

JNJ's 3Q earnings expected to be $2.21 EPS and $22.16B revenue. Recent acquisitions and drug trials impacting stock's ...

Johnson & Johnson's Q3 results exceeded expectations, with 26.5% year-over-year growth in the cardiovascular market and a 5.4 ...

Matt Miksic, an analyst from Barclays, maintained the Hold rating on Johnson & Johnson (JNJ – Research Report). The associated price ...

RBC Capital raised the firm’s price target on Johnson & Johnson to $181 from $178 and keeps an Outperform rating on the ...

Johnson & Johnson (NYSE:JNJ) is scheduled to announce Q3 earnings results on Tuesday, October 15th, before market open.